ADVERUM BIOTECHNOLOGIES INC (ADVM) Forecast, Price Target & Analyst Ratings
NASDAQ:ADVM • US00773U2078
4.36 USD
+0.1 (+2.35%)
At close: Dec 8, 2025
4.6 USD
+0.24 (+5.5%)
After Hours: 12/8/2025, 8:00:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ADVERUM BIOTECHNOLOGIES INC (ADVM).
Forecast Snapshot
Consensus Price Target
$5.00
+ 14.63% Upside
Next Earnings Forecast
Release DateMar 16, 2026
PeriodQ4 / 2025
EPS Estimate-$1.47
Revenue Estimate339.997K
ChartMill Buy Consensus
76.67%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.00
Upside
+ 14.63%
From current price of $4.36 to mean target of $5.00, Based on 12 analyst forecasts
Low
$4.04
Median
$5.10
High
$5.78
Price Target Revisions
1 Month
-56.25%
3 Months
-74.87%
Price Target Summary
12 analysts have analysed ADVM and the average price target is 5 USD. This implies a price increase of 14.63% is expected in the next year compared to the current price of 4.36.
The average price target has been revised downward by 74.87% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
76.67%
ADVM was analyzed by 12 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about ADVM.
In the previous month the buy percentage consensus was at a similar level.
ADVM was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-17 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-10-28 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-09-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-26 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-15 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-16 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-05 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-08-14 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-13 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-06-25 | Oppenheimer | Initiate | Outperform |
| 2024-05-15 | Truist Securities | Maintains | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-30 | HC Wainwright & Co. | Initiate | Buy |
| 2024-04-29 | Mizuho | Maintains | Buy -> Buy |
| 2024-03-19 | Chardan Capital | Reiterate | Buy -> Buy |
| 2024-03-19 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-02-06 | Mizuho | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 16, 2026
PeriodQ4 / 2025
EPS Estimate-$1.47
Revenue Estimate339.997K
Revenue Q2QN/A
EPS Q2Q24.89%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
-97.37%
Revenue (3 Months)
-98.24%
EPS (1 Month)
-68.81%
EPS (3 Months)
-138.96%
Next Earnings Summary
ADVM is expected to report earnings on 3/16/2026. The consensus EPS estimate for the next earnings is -1.47 USD and the consensus revenue estimate is 340.00K USD.
The next earnings revenue estimate has been revised downward by 98.24% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 3.6M | 1M -72.22% | 12.92M 1,192.00% | 255K -98.03% | 291.383K 14.27% | -100.00% | 17.034M | 85.782M 403.59% | 118.01M 37.57% | 233.68M 98.02% | |
| EBITDA YoY % growth | -148.507M -5.79% | -118.147M 20.44% | -135.506M -14.69% | -205.02M -51.30% | -226.44M -10.45% | -271.32M -19.82% | -340.68M -25.56% | -392.7M -15.27% | -381.48M 2.86% | -318.24M 16.58% | -214.2M 32.69% | |
| EBIT YoY % growth | -155.035M -6.90% | -123.791M 20.15% | -139.159M -12.41% | -191.462M -37.58% | -189.432M 1.06% | -187.382M 1.08% | -223.169M -19.10% | -206.527M 7.46% | -142.877M 30.82% | -73.313M 48.69% | -110.568M -50.82% | |
| Operating Margin | N/A | -3,438.64% | -13,915.90% | -1,481.90% | -74,287.12% | -64,307.86% | N/A | -1,212.44% | -166.56% | -62.12% | -47.32% | |
| EPS YoY % growth | -15.50 -4.73% | -11.60 25.16% | -5.65 51.29% | -6.66 -17.80% | -3.67 44.90% | -3.12 14.95% | -3.87 -24.12% | -4.52 -16.73% | -4.62 -2.26% | -2.52 45.47% | 0.20 108.10% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.47 24.89% | -1.26 44.01% | -1.23 47.26% | -1.29 36.69% | -0.44 69.86% |
| Revenue Q2Q % growth | 339.997K | -100.00% | |||
| EBITDA Q2Q % growth | -53.04M -36.12% | -55.08M -25.58% | -56.1M -14.58% | -57.12M -23.26% | -56.1M -5.77% |
| EBIT Q2Q % growth | -51.973M -21.95% | -54.06M -26.14% | -56.1M -13.78% | -57.12M -18.94% | -58.523M -12.60% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
13.13%
EPS Next 5 Year
3.72%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-34.14%
Revenue Next 5 Year
75.61%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-34.82%
EBIT Next 5 Year
-28.82%
ADVERUM BIOTECHNOLOGIES INC / ADVM Forecast FAQ
What is the price target for ADVM stock?
12 analysts have analysed ADVM and the average price target is 5 USD. This implies a price increase of 14.63% is expected in the next year compared to the current price of 4.36.
Can you provide the upcoming earnings date for ADVERUM BIOTECHNOLOGIES INC?
ADVERUM BIOTECHNOLOGIES INC (ADVM) will report earnings on 2026-03-16, after the market close.
What are the consensus estimates for ADVM stock next earnings?
The consensus EPS estimate for the next earnings of ADVERUM BIOTECHNOLOGIES INC (ADVM) is -1.47 USD and the consensus revenue estimate is 340.00K USD.
What is the expected long term growth rate for ADVM stock?
The expected long term growth rate for ADVERUM BIOTECHNOLOGIES INC (ADVM) is -34.14%.